The National Health Service (NHS) has released new guidelines advocating for the examination of up to four million women and non-binary individuals with irregular menstrual cycles for polyendocrine metabolic ovarian syndrome (PMOS), previously referred to as polycystic ovarian syndrome (PCOS). This condition, which affects around 13% of women of reproductive age, is often overlooked, leaving many to suffer from its effects without proper diagnosis or management.
Understanding PMOS and Its Symptoms
PMOS presents a range of symptoms that can significantly impact quality of life. These include irregular, extremely short, prolonged, or absent menstrual periods, elevated testosterone levels, and the presence of multiple small follicles in the ovaries. The condition has also been linked to an increased risk of serious health issues, such as type 2 diabetes, cardiovascular problems, sleep apnoea, fatty liver disease, and mental health challenges, as well as complications during pregnancy.
Despite its prevalence, the National Institute for Health and Care Excellence (NICE) has pointed out that PMOS is frequently underdiagnosed and inconsistently treated across healthcare settings. The newly drafted guidelines aim to change this by providing clearer pathways for diagnosis and management.
Expanded Guidelines for Diagnosis and Care
The recent NICE guidelines extend their recommendations to encompass individuals over the age of 10, including adult women, transgender men, and non-binary individuals who have not undergone gender reassignment therapy or surgery. For those suspected of having PMOS, healthcare providers are advised to conduct blood tests to assess both male and female hormone levels, and in certain cases, ultrasounds may also be warranted.
Critically, the guidelines emphasise that PMOS should not be dismissed in post-menopausal women or those with eating disorders—conditions that disproportionately affect individuals with PMOS. Furthermore, the guidelines highlight the need for awareness that PMOS may be more prevalent among women of Black, Asian, and mixed ethnic backgrounds, urging healthcare professionals to consider this when evaluating symptoms.
Once diagnosed, individuals with PMOS are recommended to have annual reviews to monitor their symptoms, which can include menstrual irregularities and excess hair growth. These reviews also cover essential health aspects such as cardiovascular health, diabetes risk, obesity, and mental health care.
IVF and Treatment Options
The guidelines stipulate that women with PMOS who meet the established NICE criteria should be offered in vitro fertilisation (IVF) as a treatment option. However, NICE has advised against providing laser hair removal or light therapies for excessive hair growth, citing that such treatments may not be cost-effective, estimating that they could impose up to £100 million in annual costs on the NHS in England.
The draft guidelines are informed by evidence-based research from Monash University and are aligned with practices in over 100 countries, aiming to improve consistency in care for those affected by PMOS.
Expert Reactions and Future Consultations
Marieanne Ledingham, a consultant clinical advisor for women’s and reproductive health at NICE, emphasised the importance of recognising PMOS as a common yet often neglected condition. “Recommending a simple annual review is an important step towards ensuring people get the ongoing care and monitoring they need,” she stated. This new guidance is expected to enhance awareness, encourage earlier diagnosis, and improve management of PMOS.
The consultation period for these draft guidelines remains open until 11 August 2026, with finalised recommendations anticipated in December 2026. Dr Rachel Reid-McCann, an Oxford University researcher, echoed the significance of timely investigations for those with irregular periods, noting the potential for better health outcomes and access to necessary treatments once diagnosed.
Janet Lindsay, CEO of the charity Wellbeing of Women, welcomed the guidelines, underscoring the historical challenges faced by women with PMOS in securing timely diagnoses and consistent care. She highlighted the need to address the inequalities in healthcare access, particularly for women from Black, Asian, and other minoritised communities, who often encounter additional barriers to receiving proper care.
Why it Matters
The introduction of these guidelines marks a pivotal shift in the recognition and management of PMOS, a condition that has long been overshadowed in women’s health discourse. By advocating for thorough investigations and regular monitoring, the NHS aims to dismantle the barriers that have perpetuated health inequalities. For millions, this could translate into improved health outcomes, enhanced quality of life, and a more equitable healthcare landscape that acknowledges and addresses the complexities of reproductive health.
